{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:41:47Z","timestamp":1788432107941,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10072-025-08692-9","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T01:18:38Z","timestamp":1769044718000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of IPX203 in Parkinson\u2019s patients: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1254-4289","authenticated-orcid":false,"given":"Asmaa Zakria","family":"Alnajjar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3637-6221","authenticated-orcid":false,"given":"Maha","family":"AbuZarifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2038-0305","authenticated-orcid":false,"given":"Khaled A.","family":"Zakout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7975-1154","authenticated-orcid":false,"given":"Younis","family":"Alemour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0511-2429","authenticated-orcid":false,"given":"Moaz Elsayed","family":"Abouelmagd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1101-0442","authenticated-orcid":false,"given":"Siham","family":"Alshawamreh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3400-3026","authenticated-orcid":false,"given":"Tayef","family":"Aldirawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0692-6309","authenticated-orcid":false,"given":"Mostafa","family":"Meshref","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"issue":"11","key":"8692_CR1","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","author":"GBDPD Cisnhy","year":"2018","unstructured":"Cisnhy GBDPD (2018) Global, regional, and national burden of parkinson\u2019s disease, 1990\u20132016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol 17(11):939\u2013953. https:\/\/doi.org\/10.1016\/S1474-4422(18)30295-3","journal-title":"Lancet Neurol"},{"issue":"13","key":"8692_CR2","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/mds.25945","volume":"29","author":"T Pringsheim","year":"2014","unstructured":"Pringsheim T, Jette N, Frolkis A, Steeves TDL (2014) The prevalence of parkinson\u2019s disease: a systematic review and meta-analysis. Mov Disord 29(13):1583\u20131590. https:\/\/doi.org\/10.1002\/mds.25945","journal-title":"Mov Disord"},{"issue":"9","key":"8692_CR3","doi-asserted-by":"publisher","first-page":"754","DOI":"10.2174\/1389557519666191104110908","volume":"20","author":"BLB Marino","year":"2020","unstructured":"Marino BLB, Cardoso FEC, Chagas MHN, Tumas V, Barbosa ER (2020) Parkinson\u2019s disease: a review from pathophysiology to treatment. Mini-Rev Med Chem 20(9):754\u2013767. https:\/\/doi.org\/10.2174\/1389557519666191104110908","journal-title":"Mini-Rev Med Chem"},{"key":"8692_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.lfs.2019.03.057","volume":"226","author":"C Raza","year":"2019","unstructured":"Raza C, Anjum R, Shakeel NUA (2019) Parkinson\u2019s disease: mechanisms, translational models and management strategies. Life Sci 226:77\u201390. https:\/\/doi.org\/10.1016\/j.lfs.2019.03.057","journal-title":"Life Sci"},{"issue":"9","key":"8692_CR5","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1111\/j.1468-1331.2009.02697.x","volume":"16","author":"AHV Schapira","year":"2009","unstructured":"Schapira AHV, Emre M, Jenner P, Poewe W (2009) Levodopa in the treatment of parkinson\u2019s disease. Eur J Neurol 16(9):982\u2013989. https:\/\/doi.org\/10.1111\/j.1468-1331.2009.02697.x","journal-title":"Eur J Neurol"},{"issue":"2","key":"8692_CR6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1055\/s-0037-1602423","volume":"37","author":"ME Freitas","year":"2017","unstructured":"Freitas ME, Hess CW, Fox SH (2017) Motor complications of dopaminergic medications in parkinson\u2019s disease. Semin Neurol 37(2):147\u2013157. https:\/\/doi.org\/10.1055\/s-0037-1602423","journal-title":"Semin Neurol"},{"issue":"Suppl 1","key":"8692_CR7","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/S1353-8020(09)70005-7","volume":"15","author":"F Stocchi","year":"2009","unstructured":"Stocchi F (2009) The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of parkinson\u2019s disease. Parkinsonism Relat Disord 15(Suppl 1):S9\u2013S15. https:\/\/doi.org\/10.1016\/S1353-8020(09)70005-7","journal-title":"Parkinsonism Relat Disord"},{"key":"8692_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2023.100197","volume":"8","author":"P LeWitt","year":"2023","unstructured":"LeWitt P, Isaacson S, Pahwa R, Ellenbogen A, Espay AJ, Hauser RA, Fernandez HH, Stocchi F, Ondo WG, Zeitlin L, Banisadr G, Fisher S, Visser H, D\u2019Souza R (2023) Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation. Clinical Parkinsonism & Related Disorders 8:100197. https:\/\/doi.org\/10.1016\/j.prdoa.2023.100197","journal-title":"Clinical Parkinsonism & Related Disorders"},{"issue":"10","key":"8692_CR9","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1001\/jamaneurol.2023.2679","volume":"80","author":"RA Hauser","year":"2023","unstructured":"Hauser RA, Espay AJ, Ellenbogen AL, Fernandez HH, Isaacson SH, LeWitt PA, Ondo WG, Pahwa R, Schwarz J, Stocchi F, Zeitlin L, Banisadr G, Fisher S, Visser H, D\u2019Souza R (2023) IPX203 vs immediate-release carbidopa-levodopa for the treatment of motor fluctuations in Parkinson disease: the RISE-PD randomized clinical trial. JAMA Neurol 80(10):1062\u20131069. https:\/\/doi.org\/10.1001\/jamaneurol.2023.2679","journal-title":"JAMA Neurol"},{"key":"8692_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"8692_CR11","doi-asserted-by":"crossref","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D. Movement Disorder Society UPDRS Revision Task Force (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord 23(15):2129\u20132170","DOI":"10.1002\/mds.22340"},{"issue":"1","key":"8692_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.2003.tb07458.x","volume":"991","author":"S Fahn","year":"2003","unstructured":"Fahn S (2003) Description of Parkinson\u2019s disease as a clinical syndrome. Ann N Y Acad Sci 991(1):1\u201314","journal-title":"Ann N Y Acad Sci"},{"key":"8692_CR13","unstructured":"Stacy MA (2002) The wearing-off phenomenon and the use of a COMT inhibitor. Neurology, 58(4_suppl_1)."},{"key":"8692_CR14","doi-asserted-by":"publisher","unstructured":"Deeks JJ, Higgins JP, Altman DG (2019) Analysing data and undertaking meta-analyses. Cochrane handbook for systematic reviews of interventions. Wiley-Blackwell, pp 241\u2013284. https:\/\/doi.org\/10.1002\/9781119536604.ch10","DOI":"10.1002\/9781119536604.ch10"},{"key":"8692_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JA Sterne","year":"2011","unstructured":"Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, Carpenter J, R\u00fccker G, Harbord RM, Schmid CH, Tetzlaff J, Deeks JJ, Peters J, Macaskill P, Schwarzer G, Duval S, Altman DG, Moher D, Higgins JP (2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 343:d4002. https:\/\/doi.org\/10.1136\/bmj.d4002","journal-title":"BMJ"},{"issue":"5","key":"8692_CR16","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/WNF.0000000000000354","volume":"42","author":"NB Modi","year":"2019","unstructured":"Modi NB, Mittur A, Dinh P, Rubens R, Gupta S (2019) Pharmacodynamics, efficacy, and safety of IPX203 in Parkinson disease patients with motor fluctuations. Clin Neuropharmacol 42(5):149\u2013156. https:\/\/doi.org\/10.1097\/WNF.0000000000000354","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"8692_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/WNF.0000000000000314","volume":"42","author":"NB Modi","year":"2019","unstructured":"Modi NB, Mittur A, Rubens R, Khanna S, Gupta S (2019) Single-dose pharmacokinetics and pharmacodynamics of IPX203 in patients with advanced Parkinson disease: a comparison with immediate-release carbidopa-levodopa and with extended-release carbidopa-levodopa capsules. Clin Neuropharmacol 42(1):4\u20138. https:\/\/doi.org\/10.1097\/WNF.0000000000000314","journal-title":"Clin Neuropharmacol"},{"key":"8692_CR18","unstructured":"Hauser RA (n.d.) (ed) Extended-release carbidopa-levodopa: How is IPX203 different from IPX066? 5th Pan American Parkinson\u2019s Disease and Movement Disorders Congress, Cartagena, Colombia. https:\/\/pdexpertinstitute.com\/extended-release-carbidopa-levodopa-how-is-ipx203-different-from-ipx066\/"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08692-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08692-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08692-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T17:02:53Z","timestamp":1771347773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08692-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["8692"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08692-9","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"5 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent and Ethical approval were not sought for this paper because it included no direct interaction with human participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent and ethical approval"}},{"value":"The authors declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"CRD42024574303.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prospero registration"}}],"article-number":"187"}}